

**Annexure 1: Consultation Response Form**

**REQUEST FOR COMMENT: Updating of Health Technology Assessment** **Methods Guide to Inform the Selection of Medicines to the National Essential Medicines List**

**Consultation: 9 July 2021 – 4 October 2021**

Thank you for participating in the consultation on the Health Technology Assessment (HTA) Methods Guide to Inform the Selection of Medicines to the National Essential Medicines List (EML).

We are interested in hearing your thoughts about the following:

* Are the methods specifications *appropriate* in the South African context?
* Are the methods specifications *feasible* in the South African context?
* Is the *structure* of the HTA Methods Guide appropriate?
* Is the language and approach in the HTA Methods Guide *clear and understandable*?
* Are there any *major gaps* in the methods that may be useful for the assessment of medicines in South Africa?
* Are there any *factual inaccuracies* that should be corrected?
* Specific feedback on the sections in the HTA Methods Guide.

The information collected will be used to inform and update the HTA Methods Guide that will be used for the assessment and appraisal of medicines when considering selection to the National Standard Treatment Guidelines and Essential Medicines List.

We invite comments from any interested individuals and institutions. We regret that we will not provide individual response to comments or suggestions.

When responding, we ask consultees to keep in mind that the aim of the HTA Methods Guide is to clarify, formalize and standardize existing HTA methodological practice for generating evidence to inform decision-making in this technical area. The HTA Methods Guide does not provide guidance on procedural aspects of the technology assessment process, e.g. governance structures, decision-making frameworks, or stakeholder engagement. We cannot incorporate any comments that falls outside of the scope of the Methods Guide.

***Submitting your responses***

Please use this consultation form to provide your comments. You do not have to provide comments for all sections.

Consultation responses and requests for further information should be emailed to Janine Jugathpal on [Janine.Jugathpal@health.gov.za](mailto:maryke.wilkinson@gmail.com) by 4 October 2021.

Your co-operation in this regard is appreciated.

# About you

To help us understand your comments, please indicate the name of the organisation and department you work for next to the relevant category. Alternatively, if you are responding as an individual, please provide your job title or description of your role.

**Responding on behalf of an organisation**

|  |  |
| --- | --- |
| Category | Name of organisation and department |
| Department of Health |  |
| Academic body |  |
| Research unit |  |
| Professional organisation |  |
| Public / patient advocacy group |  |
| Industry body |  |
| Life sciences consultancy |  |
| Medical aid |  |
| Regulatory body |  |
| Other |  |

**Responding as an individual**

Job title/ description of your role:

# Response to consultation

**GENERAL FEEDBACK**

|  |
| --- |
| 1. Are the methods specifications *appropriate* in the South African context? |
| *Response* |
| 1. Are the methods specifications *feasible* in the South African context? |
| *Response* |
| 1. Is the *structure* of the HTA Methods Guide appropriate? |
| *Response* |
| 1. Is the language and approach in the HTA Methods Guide *clear and understandable*? |
| *Response* |
| 1. Are there any *major gaps* in the methods that may be useful for the assessment of medicines in South Africa? |
| *Response* |
| 1. Are there any *factual inaccuracies* that should be corrected in the HTA Methods Guide? |
| *Response* |

**Specific feedback on the sections in the HTA Methods Guide**

*Please consider the appropriateness and feasibility of methods specifications, describe major gaps and factual inaccuracies identified, and provide suggestions for improvement.*

1. **INTRODUCTION**

|  |  |  |
| --- | --- | --- |
| 1.1 | HTA in South Africa’s public health system | *Response* |
| 1.1.1 | Guiding principles for HTA in South Africa | *Response* |
| 1.2 | Stakeholder engagement | *Response* |
| 1.3 | Topic prioritisation process | *Response* |
| 1.4 | Tiers of assessment | *Response* |
|  | Other comments | *Response* |

1. **TECHNOLOGY ASSESSMENT SCOPE DEVELOPMENT**

|  |
| --- |
| *Response* |

1. **ASSESSMENT**

**3.1 STAGE 1: TECHNICAL REPORT**

|  |  |  |
| --- | --- | --- |
| 3.1.1 | Clinical evidence | *Response* |
| 3.1.2 | Economic evidence | *Response* |
| 3.1.3 | Equity considerations | *Response* |
| 3.1.4 | Social value considerations | *Response* |
| 3.1.5 | Feasibility considerations | *Response* |
| 3.1.6 | Recommendations | *Response* |
|  | Other comments | *Response* |

**3.2 STAGE 2: ADDITIONAL ANALYSIS**

|  |  |  |
| --- | --- | --- |
| 3.2.1 | Systematic review | *Response* |
| 3.2.2 | Cost-comparison analysis | *Response* |
| 3.2.3 | Budget impact analysis | *Response* |
| 3.2.4 | Rapid review of economic evaluations | *Response* |
| 3.2.5 | Cost-effectiveness analysis | *Response* |
| 3.2.6 | Pricing analysis | *Response* |
|  | Other comments | *Response* |

1. **EVIDENCE APPRAISAL**

|  |
| --- |
| *Response* |

**OTHER COMMENTS**

|  |
| --- |
| *Response* |